2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-183722
    SDH-IN-46
    SDH-IN-46 is a succinate dehydrogenase (SDH) inhibitor with an IC50 of 1.21 μM. SDH-IN-46 disrupts fungal respiration via mitochondrial respiratory chain enzyme targeting and exhibits broad-spectrum antifungal activity. SDH-IN-46 exhibits substantial protective effects against S. sclerotiorum on oilseed rape leaves, Rhizoctonia solani on rice leaves, and Valsa mali on apple fruits.
    SDH-IN-46
  • HY-183726
    PknB-IN-3
    PknB-IN-3 is a Mycobacterium tuberculosis Protein kinase B (PknB) inhibitor with an IC50 of 0.06 μM. PknB-IN-3 inhibits growth of Mycobacterium tuberculosis and can be used for the research of tuberculosis.
    PknB-IN-3
  • HY-183727
    SARS-CoV-2 Mpro-IN-59 98%
    SARS-CoV-2 Mpro-IN-59 is a competitive, nonpeptidic SARS-CoV-2 Mpro inhibitor. SARS-CoV-2 Mpro-IN-59 can be used for the research of covid-19.
    SARS-CoV-2 Mpro-IN-59
  • HY-183759
    Feneptamidoquin 2132414-06-1
    Feneptamidoquin (SYN551769) is a quinoline Fungicide. The combination of Feneptamidoquin and Eugenol (HY-N0337) potently inhibits mycelial growth of Botrytis cinerea. Feneptamidoquin can be used in studies related to gray mold.
    Feneptamidoquin
  • HY-183851
    KKL-55 639048-45-6 98%
    KKL-55 is a broad-spectrum antibacterial agent that inhibits the trans-translation pathway and the ClpXP protease. KKL-55 suppresses trans-translation of non-stop mRNA, interferes with the binding of EF-Tu to tmRNA, and inhibits the proteolysis of substrates by ClpXP. KKL-55 blocks spore germination of Bacillus anthracis and protects macrophages from damage induced by anthrax toxin. By virtue of its inhibitory effect on ClpXP, KKL-55 synergistically enhances the antibacterial activity of antibiotics against drug-resistant Staphylococcus aureus. KKL-55 can be used in studies related to bacterial infections.
    KKL-55
  • HY-183865
    F1414-1444 794552-29-7
    F1414-1444 is a DBPI skeleton derivative and a potent inhibitor of IspQ (Rv0338c)-targeting Mycobacterium tuberculosis. F1414-1444 binds to the membrane-bound iron-sulfur oxidoreductase IspQ, induces oxidative stress and thiol stress in bacterial cells, upregulates the expression of stress-related genes such as the SigK regulon, thereby inhibiting bacterial proliferation and exerting bactericidal activity. F1414-1444 only inhibits the Mycobacterium tuberculosis complex and Mycobacterium marinum. F1414-1444 can be used in studies related to Mycobacterium tuberculosis.
    F1414-1444
  • HY-183872
    FTR1335 851075-79-1
    FTR1335 is an Antifungal agent as well as a selective, substrate peptide-competitive, and myristoyl-CoA non-competitive inhibitor of N-myristoyltransferase CaNmt, with an IC50 of 0.49 nM against Candida albicans CaNmt. FTR1335 exhibits fungicidal activity against Candida albicans and inhibits the growth of Candida tropicalis. FTR1335 can be used in research related to Candida albicans infections.
    FTR1335
  • HY-183873
    HLB-0532247 2850362-12-6 98%
    HLB-0532247 is a cell-permeable phosphoramidate prodrug of 3'-deoxy-3',4'-didehydrocytidine (ddhC). HLB-0532247 increases the intracellular level of the endogenous antiviral nucleotide ddhCTP (HY-128788). HLB-0532247 reduces the titers of Zika virus and West Nile virus in cell cultures. HLB-0532247 can be used in studies related to Zika virus infection, West Nile virus infection, and coronavirus infection.
    HLB-0532247
  • HY-183878
    Zincov 71431-46-4 98%
    Zincov is an orally active hydroxamic acid derivative and bacterial metalloproteinase inhibitor. Zincov blocks chloride ion binding by binding to the active site of thermolysin, thereby inhibiting the hydrolysis and blood coagulation reactions catalyzed by this enzyme. Meanwhile, Zincov attenuates cytotoxicity, prevents protein degradation and ZO-1 rearrangement without affecting the functions of other common proteases. Zincov exhibits blood glucose-regulating and antioxidant activities; it reduces blood glucose levels and increases liver dry weight in diabetic rats, but elevates blood glucose levels in normal rats. Zincov is widely used in studies related to cholera and diabetes.
    Zincov
  • HY-183886
    U 80493 136816-67-6
    U 80493 is a HIV-1 reverse transcriptase inhibitor with IC50 of 20 μM. U 80493 can be used for the research of acquired immunodeficiency syndrome.
    U 80493
  • HY-183925
    Redoxal 52962-95-5
    Redoxal is a dihydroorotate dehydrogenase (DHODH) inhibitor and anti-HIV-1 agent. Redoxal induces intracellular pyrimidine depletion by inhibiting the de novo pyrimidine biosynthesis pathway, enhances the protein stability of APOBEC3G (A3G), upregulates the abundance of A3G protein in cells and progeny viral particles, thereby strengthening the host endogenous antiviral restriction mediated by A3G. Redoxal selectively targets DHOdehase at the mitochondrial level, with an IC50 of 430 nM for inhibiting DHO oxidation in human mitochondria and an IC50 of 910 nM in rat mitochondria. Redoxal can be used in studies related to HIV-1 infection.
    Redoxal
  • HY-183929
    Antiviral agent 87 346715-10-4 98%
    Antiviral agent 87 is a potent antiviral agent with low cytotoxicity in host cells. Antiviral agent 87 stabilizes prefusion HA conformation, blocks viral membrane fusion and host cell entry, and inhibits entry and replication of diverse influenza A virus subtypes. Antiviral agent 87 can be used for the research of influenza A virus infection.
    Antiviral agent 87
  • HY-183956
    GC813 2170616-59-6
    GC813 is a MERS-CoV 3CL protease (3CLpro) and MERS-CoV main protease (Mpro) inhibitor. GC813 can be used for the research of middle east respiratory syndrome.
    GC813
  • HY-183957
    (Z,E)-7,11-Hexadecadienal 96883-54-4
    (Z,E)-7,11-Hexadecadienal is a geometric isomer of Z7,Z11-16:Ald, the core component of the citrus leafminer sex pheromone. (Z,E)-7,11-Hexadecadienal acts as a sex pheromone tropism inhibitor; when mixed with the sex pheromone Z7,Z11-16:Ald, it blocks the tropism of male citrus leafminers towards the sex pheromone component. (Z,E)-7,11-Hexadecadienal can be used in insect resistance-related research.
    (Z,E)-7,11-Hexadecadienal
  • HY-183972
    Desaspidin 114-43-2 98%
    Desaspidin is an oxidative phosphorylation inhibitor and photophosphorylation inhibitor. Desaspidin uncouples mitochondrial oxidative phosphorylation, multiple chloroplast photophosphorylation pathways, and ATP synthesis linked to non-cyclic NADP reduction. Desaspidin can be used for the research of anthelmintic agent.
    Desaspidin
  • HY-184263
    CHVB-032 1309199-66-3
    CHVB-032 is an antiviral agent and SFV nsP1 inhibitor. CHVB-032 inhibits the methyltransferase and guanylyltransferase activities of nsP1, blocks viral RNA capping process, and suppresses post-entry steps in CHIKV replication. CHVB-032 inhibits CHIKV replication across different isolates, but shows no activity against other alphaviruses. CHVB-032 can be used in research related to chikungunya fever and CHIKV infection.
    CHVB-032
  • HY-184264
    CHVB-066 1309199-94-7 98%
    CHVB-066 is an alphavirus non-structural protein nsP1 inhibitor that exhibits varying degrees of inhibitory activity against nsP1 of CHIKV and VEEV. CHVB-066 inhibits MTase and GTase activities and disrupts the capping process of viral RNA, including inhibiting CHIKV replication, reducing progeny viruses, and preventing cytopathic effects. It shows varying degrees of inhibitory activity against nsP1 of CHIKV and VEEV but lacks anti-SFV replication activity, displays cross-resistance with MADTP series compounds, and requires nsP2/nsP3 mutations to develop complete drug resistance. This inhibitor with varying inhibitory activity against nsP1 of CHIKV and VEEV can be widely applied to relevant studies on chikungunya virus infection and chikungunya fever.
    CHVB-066
  • HY-185117
    MAC-0018315 690626-17-6 98%
    MAC-0018315 is an antibacterial agent.
    MAC-0018315
  • HY-185150
    PMEG 114088-58-3 98%
    PMEG is a nuclear DNA polymerases α, δ, and ε inhibitor that causes DNA chain termination, inhibits DNA synthesis, induces cytotoxicity in dividing cells. PMEG is an acyclic nucleotide phosphonate that forms an active phosphorylated metabolite, PMEG diphosphate, within cells. PMEG has activity against leukemia and melanoma in rodent models. PMEG has poor cell permeability; its prodrug is Rabacfosadine (GS-9219) (HY-13640). PMEG shows antiviral activity against against various DNA virus infections including murine cytomegalovirus (MCMV) and human cytomegalovirus (HCMV). PMEG can be used for the research of non-hodgkin's lymphoma[1][2].
    PMEG
  • HY-185177
    Antifungal agent 156 2446126-42-5
    Antifungal agent 156 (Ex.1-123) is a heterocyclic pyridazine compound and a phytopathogenic fungal control agent, which can be used in studies related to phytopathogenic fungal infection.
    Antifungal agent 156
Cat. No. Product Name / Synonyms Application Reactivity